

**REMARKS/ARGUMENTS**

In the Notification of Defective Response mailed on May 22, 2008, the Office indicated that an amendment directing entry of the sequence listing into the application is required to place the application into conformance with the requirements of 37 CFR 1.821-1.825. In response, the specification has been amended herein to direct entry of the substitute paper and computer-readable copies of the sequence listing being submitted concurrently herewith into the application.

The specification has been amended at page 34, line 9, to replace “[SEQ ID NO:43]” with --[SEQ ID NO:44]--. Moreover, the specification has been amended at page 39, Table 9, to insert the phrase --and translated peptide sequence-- after the word “Sequence.” Additionally, --SeqID No: 43-- has been added prior to “Glu” at page 39, Table 9. The paper and computer-readable copies of the sequence listing submitted herewith reflect these amendments.

Should the Examiner have any questions concerning this response, the Examiner is respectfully invited to contact the undersigned at the telephone number set forth below.

The Commissioner is hereby authorized to charge payment of any fees associated with this communication, or credit any overpayment, to Deposit Account No. 08-2461. Such authorization includes authorization to charge fees for extensions of time, if any, under 37 C.F.R. §1.17 and also should be treated as a constructive petition for an extension of time in this reply or any future reply pursuant to 37 C.F.R. §1.136.

Respectfully submitted,



Andrea M. Wilkovich  
Registration No.: 53,773

HOFFMANN & BARON, LLP  
6900 Jericho Turnpike  
Syosset, New York 11791  
(973) 331-1700